16 Oct 2026 · Indonesia

Indonesia Regulatory Update: BPOM Forum & Natural Medicine Enforcement (Oct 9-16, 2026)

BPOM convened a strategic forum on drug and food supervision, highlighting compliance gaps, ethylene oxide food safety risks, and digital oversight. Simultaneously, the agency canceled marketing authorizations for three natural medicine products containing the novel PDE5 inhibitor pyrimidenafil, uncovering 35 additional illegal products.

Recent regulatory activity in Indonesia underscores evolving supervisory priorities across pharmaceuticals and food safety.

Strategic Forum Outcomes

BPOM held a cross-sector forum to advance evidence-based policy analysis for drug and food supervision. Key takeaways include:

The 2025 Compliance Index for business actors was highlighted as a benchmark for performance assessment.
Food safety concerns related to ethylene oxide exposure were emphasized as a critical risk area.
New sampling and testing guidelines were introduced to strengthen market surveillance.

Natural Medicine Enforcement Action

BPOM identified the novel PDE5 inhibitor pyrimidenafil (a BKO) in three natural medicine products—EXIE, YUBOKKI, and DURAMAX—and immediately canceled their marketing authorizations. An additional review uncovered 35 other natural medicine products containing prohibited substances, marking a significant crackdown on adulteration practices aimed at circumventing standard testing protocols.

Full forum announcement | Pyrimidenafil enforcement details

#PECANSolutions #RegulatoryAffairs #PharmaRegulation #AsiaMarketAccess #Indonesia #bpom #pyrimidenafil #indonesiaregulation

Related markets: Indonesia

Ready to Enter Asian Markets?

PECAN.Solutions is your trusted partner for navigating the complex regulatory landscape of Asian pharmaceutical markets. With our network of local experts and proven track record since 2007, we can help you bring your products to market efficiently and compliantly.